Rocket VR Health, a virtual reality digital therapeutics company transforming mental health treatments with interactive mindfulness meditations and evidence-based digital therapeutics, has announced it has initiated a randomised control trial with Massachusetts General Hospital (MGH).
The 80-patient trial is examining the feasibility and preliminary efficacy of RVH's virtual reality digital therapeutic in improving quality of life, symptom burden, psychological distress and self-efficacy in adult patients with blood cancers admitted for hematopoietic stem cell transplantation (HCT) at MGH. Patients undergoing this type of treatment experience immense physical and psychological symptoms during a prolonged four-week hospitalisation and endure significant short-term and long-term distress that affects their quality of life (QOL) and their physical and psychological well-being.
MGH is Harvard Medical School's largest teaching hospital. The Cancer Outcomes Research and Education Program (CORE) at MGH conducts innovative research and educational programs to improve the experience and outcomes of patients and caregivers across the continuum of cancer care.
Digital Health Interventions that support patients in reducing distress and improving psychosocial well-being are lacking and RVH and MGH partnered in early 2021 to co-develop this first of its kind evidence-based VR solution. The therapeutic recovery program leverages lessons learned from evidence-based palliative care interventions for patients undergoing HCT that were studied for years by the MGH team. The comprehensive 4-week therapeutic intervention combines interactive therapeutic experiences, high-definition doctor holograms and meditations taking place at breathtaking nature-based locations.
Click here to read the original news story.
Looking for expert insights in Clinical Trials Innovation? Join the HealthXL Masterclass on ‘Design and Control Conditions for Clinical Trials of Digital Health Solutions’ on 29th March. Click here to Request to Join.